Oppenheimer & CO Inc Voyager Therapeutics, Inc. Transaction History

Oppenheimer & CO Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 11, 2020	SELL	$8.05 - $14.21 $148,804 - $262,671	-18,485 Closed	0 $0
Q1 2020 May 08, 2020	BUY	$6.8 - $14.66 $8,540 - $18,412	1,256 Added 7.29%	18,485 $169,000
Q4 2019 Feb 07, 2020	BUY	$12.82 - $16.85 $89 - $117	7 Added 0.04%	17,229 $240,000
Q3 2019 Oct 31, 2019	SELL	$16.31 - $28.29 $8,530 - $14,795	-523 Reduced 2.95%	17,222 $296,000
Q2 2019 Aug 09, 2019	SELL	$19.18 - $27.88 $76 - $111	-4 Reduced 0.02%	17,745 $483,000
Q1 2019 Apr 24, 2019	BUY	$8.0 - $19.66 $544 - $1,336	68 Added 0.38%	17,749 $339,000
Q4 2018 Jan 29, 2019	SELL	$8.59 - $18.05 $52,888 - $111,133	-6,157 Reduced 25.83%	17,681 $166,000
Q3 2018 Oct 26, 2018	BUY	$17.11 - $21.74 $31,448 - $39,958	1,838 Added 8.35%	23,838 $452,000
Q2 2018 Aug 10, 2018	BUY	$16.76 - $23.92 $100,560 - $143,520	6,000 Added 37.5%	22,000 $430,000
Q4 2017 Feb 07, 2018	SELL	$12.26 - $25.88 $16,734 - $35,326	-1,365 Reduced 7.86%	16,000 $266,000
Q3 2017 Nov 09, 2017	BUY	$8.37 - $20.59 $145,345 - $357,545	17,365	17,365 $357,000

130

34.7M

39.7K

34.6K

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $208M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.